<p>通過超過 70 年的卓越職業生涯，沃倫·巴菲特展示了成功投資的藍圖。他的紀律性方法，專注於基本面強勁的高質量公司，並以長期視角為基礎，在 2025 年初股市波動的背景下，或許比以往任何時候都更為重要。</p>
<p>在巴菲特的領導下，<strong>伯克希爾·哈撒韋</strong>(NYSE: BRK.A)(NYSE: BRK.B) 在過去幾十年中擊敗了 <strong>標準普爾 500 指數</strong>(^GSPC 1.81%) 的回報，甚至在撰寫時以令人印象深刻的 9% 的年初至今回報率超越了它。該集團的股票投資組合為零售投資者提供了一個堅實的投資思路起點。</p>
<p>以下是我認為現在值得強烈購買的兩隻巴菲特股票。最棒的是，你只需不到 300 美元就可以購買每隻股票的一股，開始你的投資組合。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTQyMTIvZGVmZW5zaXZlLXN0b2Nrcy13YXJyZW4tYnVmZmV0dC1vd25zLmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTQyMTIvZGVmZW5zaXZlLXN0b2Nrcy13YXJyZW4tYnVmZmV0dC1vd25zLmpwZyZ3PTcwMA"/></p>
<p>圖片來源：The Motley Fool。</p>
<h2>1. 克羅格</h2>
<p>由於市場對美國經濟強度的焦慮以及特朗普政府新貿易關税即將產生的影響，今年的投資環境變得具有挑戰性。然而，<strong>克羅格</strong>(KR 0.52%) 的股票卻逆勢而上，年初至今回報率達到了 9%。</p>
<p>這家雜貨連鎖店在多個品牌下運營超過 2700 家門店，包括 King Soopers、Ralphs 和 Smith's。作為消費品領域的領導者，該公司持續盈利併產生強勁的自由現金流，這與巴菲特傳統上青睞的投資類型相符。實際上，伯克希爾·哈撒韋擁有該公司 7.6% 的流通股。</p>
<p>更重要的是，克羅格的財務業績和前景依然穩健，捕捉到不受貿易戰影響的食品穩定需求。對於 2025 年，該公司預計銷售將持續增長，目標調整後的每股收益（EPS）在 4.60 美元至 4.80 美元之間，較去年中值增長 5.1%。</p>
<p>克羅格作為一隻股息增長股票脱穎而出，在過去五年中將季度支付翻倍，當前每股支付為 0.32 美元，收益率為 1.9%。</p>
<p>管理層最近的評論表達了對進一步股息增長的信心，同時還在進行股票回購授權。克羅格簡單而高質量的業務為股票提供了更多上漲空間，長期回報股東。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png"/></p>
<p>KR 股息收益率數據來源於 YCharts</p>
<h2>2. 達維塔</h2>
<p><strong>達維塔</strong>(DVA 1.38%) 是另一隻可以代表防禦性投資的巴菲特股票，能夠抵禦經濟波動。這家醫療巨頭是美國最大的醫療服務提供商之一，在 13 個其他國家也在不斷擴展，專注於腎臟透析服務。</p>
<p>去年為超過 281,000 名患者提供服務，進行了超過 2900 萬次透析治療，該業務受益於治療的重複性和救命特性，受到美國終末期腎病（ESRD）項目中獨特聯邦立法的覆蓋，擴大了對患者的醫療保險覆蓋。</p>
<p>很容易看出巴菲特為何喜歡這個高盈利的行業領導者。伯克希爾·哈撒韋擁有該公司約 44% 的流通股，這是自 2011 年首次購買以來逐步建立的股份。</p>
<p>截至 2024 年 12 月 31 日的完整年度，總收入為 128 億美元，同比增長 5.6%。或許更大的故事是盈利能力的躍升，調整後的每股收益達到 9.68 美元，比去年增長 26%，這得益於更高的定價和醫療保險報銷率。如今，達維塔作為一個引人注目的投資機會脱穎而出，結合了持續的盈利增長和吸引人的估值。</p>
<p>儘管過去一年股票上漲了 8%，但其股票的交易價格僅為 2025 年每股收益的 13 倍，作為前瞻性市盈率（P/E），遠低於該公司 10 年平均的收益倍數，後者接近 17。我認為達維塔的股票被低估，並且在未來幾年有良好的回報潛力——這一觀點巴菲特可能會贊同。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png"/></p>
<p>DVA 市盈率（前瞻性）數據來源於 YCharts</p>
<h2>為什麼這些股票是贏家</h2>
<p>儘管股市在短期內可能不可預測，但巴菲特堅定的耐心和對長期戰略的承諾為每位投資者提供了重要的教訓。在我看來，克羅格和達維塔是適合多元化投資組合的優秀股票，可以應對任何市場環境。</p>

克羅格

<p>沃倫·巴菲特的投資策略強調高質量公司及其強大的基本面。目前，有兩隻股票脱穎而出：克羅格和達維塔。克羅格表現出韌性，今年迄今為止回報率達到 9%，其背後是穩健的財務狀況和不斷增長的股息。達維塔作為腎臟透析領域的領導者，收入和盈利能力顯著增長，股票的市盈率低於其歷史平均水平。這兩隻股票都推薦給希望在市場波動中建立多元化投資組合的投資者</p>

<p>Through a remarkable career spanning more than 70 years, Warren Buffett has demonstrated a blueprint for investing success. His disciplined approach, focusing on high-quality companies with strong fundamentals, anchored through a long-term perspective, is perhaps more important than ever amid the stock market volatility at the start of 2025.</p>
<div class="lb-trans"><p>通過超過 70 年的卓越職業生涯，沃倫·巴菲特展示了成功投資的藍圖。他的紀律性方法，專注於基本面強勁的高質量公司，並以長期視角為基礎，在 2025 年初股市波動的背景下，或許比以往任何時候都更為重要。</p>
</div><p>Under Buffett's leadership, <strong>Berkshire Hathaway</strong>(NYSE: BRK.A)(NYSE: BRK.B) has crushed the returns of the <strong>S&amp;P 500</strong>(^GSPC 1.81%) over the last several decades, and is even outperforming with an impressive 9% return year to date at the time of writing. The conglomerate's stock portfolio offers retail investors a solid starting point for investment ideas.</p>
<div class="lb-trans"><p>在巴菲特的領導下，<strong>伯克希爾·哈撒韋</strong>(NYSE: BRK.A)(NYSE: BRK.B) 在過去幾十年中擊敗了 <strong>標準普爾 500 指數</strong>(^GSPC 1.81%) 的回報，甚至在撰寫時以令人印象深刻的 9% 的年初至今回報率超越了它。該集團的股票投資組合為零售投資者提供了一個堅實的投資思路起點。</p>
</div><p>Here are two Buffett stocks that I believe are strong buys right now. The best part is that you'll need less than $300 to pick up one share of each to get your portfolio started.</p>
<div class="lb-trans"><p>以下是我認為現在值得強烈購買的兩隻巴菲特股票。最棒的是，你只需不到 300 美元就可以購買每隻股票的一股，開始你的投資組合。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTQyMTIvZGVmZW5zaXZlLXN0b2Nrcy13YXJyZW4tYnVmZmV0dC1vd25zLmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F814212%2Fdefensive-stocks-warren-buffett-owns.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: The Motley Fool.</p>
<div class="lb-trans"><p>圖片來源：The Motley Fool。</p>
</div><h2>1. Kroger</h2>
<div class="lb-trans"><h2>1. 克羅格</h2>
</div><p>Market anxiety over the strength of the U.S. economy and the looming impact of new trade tariffs introduced by the Trump administration has created a challenging investing environment this year. Yet shares of <strong>Kroger</strong>(KR 0.52%) have defied the broader stock market sell-off, delivering a 9% return year to date.</p>
<div class="lb-trans"><p>由於市場對美國經濟強度的焦慮以及特朗普政府新貿易關税即將產生的影響，今年的投資環境變得具有挑戰性。然而，<strong>克羅格</strong>(KR 0.52%) 的股票卻逆勢而上，年初至今回報率達到了 9%。</p>
</div><p>The grocery chain operates more than 2,700 stores under a variety of brands, including King Soopers, Ralphs, and Smith's. The company's profile as a leader in consumer staples, generating consistent profitability and strong underlying free cash flows, aligns with the type of investment Buffett has traditionally favored. Indeed, Berkshire Hathaway owns 7.6% of the company's outstanding shares.</p>
<div class="lb-trans"><p>這家雜貨連鎖店在多個品牌下運營超過 2700 家門店，包括 King Soopers、Ralphs 和 Smith's。作為消費品領域的領導者，該公司持續盈利併產生強勁的自由現金流，這與巴菲特傳統上青睞的投資類型相符。實際上，伯克希爾·哈撒韋擁有該公司 7.6% 的流通股。</p>
</div><p>More importantly, Kroger's financial results and forward outlook remain solid, capturing steady demand for food that's unaffected by the trade war. For 2025, the company anticipates continued sales growth, targeting adjusted earnings per share (EPS) between $4.60 and $4.80, which represents a 5.1% increase at the midpoint compared to the previous year.</p>
<div class="lb-trans"><p>更重要的是，克羅格的財務業績和前景依然穩健，捕捉到不受貿易戰影響的食品穩定需求。對於 2025 年，該公司預計銷售將持續增長，目標調整後的每股收益（EPS）在 4.60 美元至 4.80 美元之間，較去年中值增長 5.1%。</p>
</div><p>Kroger stands out as a dividend growth stock, having doubled its quarterly payment over the past five years to the current rate of $0.32 per share, yielding 1.9%.</p>
<div class="lb-trans"><p>克羅格作為一隻股息增長股票脱穎而出，在過去五年中將季度支付翻倍，當前每股支付為 0.32 美元，收益率為 1.9%。</p>
</div><p>Recent comments from management express confidence in further dividend growth, alongside an ongoing share repurchase authorization. Kroger's simple yet high-quality business positions the stock for more upside, rewarding shareholders over the long term.</p>
<div class="lb-trans"><p>管理層最近的評論表達了對進一步股息增長的信心，同時還在進行股票回購授權。克羅格簡單而高質量的業務為股票提供了更多上漲空間，長期回報股東。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png" alt="" original-src="https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png"/></p>
<p>KR Dividend Yield data by YCharts</p>
<div class="lb-trans"><p>KR 股息收益率數據來源於 YCharts</p>
</div><h2>2. DaVita</h2>
<div class="lb-trans"><h2>2. 達維塔</h2>
</div><p><strong>DaVita</strong>(DVA 1.38%) is another Buffett stock that can represent a defensive investment, resilient to economic swings. This healthcare giant is one of the largest medical care providers in the United States, with an expanding presence in more than 13 other countries, specializing in kidney dialysis services.</p>
<div class="lb-trans"><p><strong>達維塔</strong>(DVA 1.38%) 是另一隻可以代表防禦性投資的巴菲特股票，能夠抵禦經濟波動。這家醫療巨頭是美國最大的醫療服務提供商之一，在 13 個其他國家也在不斷擴展，專注於腎臟透析服務。</p>
</div><p>Serving more than 281,000 patients and performing over 29 million dialysis treatments last year, the business benefits from the recurring and life-saving nature of the treatment, covered by unique federal legislation within the End-Stage Renal Disease (ESRD) program with expanded Medicare coverage for patients in the U.S.</p>
<div class="lb-trans"><p>去年為超過 281,000 名患者提供服務，進行了超過 2900 萬次透析治療，該業務受益於治療的重複性和救命特性，受到美國終末期腎病（ESRD）項目中獨特聯邦立法的覆蓋，擴大了對患者的醫療保險覆蓋。</p>
</div><p>It's easy to see what Buffett likes in this highly profitable industry leader. Berkshire Hathaway owns about 44% of the company's outstanding shares -- a stake it has built since its initial purchase in 2011.</p>
<div class="lb-trans"><p>很容易看出巴菲特為何喜歡這個高盈利的行業領導者。伯克希爾·哈撒韋擁有該公司約 44% 的流通股，這是自 2011 年首次購買以來逐步建立的股份。</p>
</div><p>For the full year ended Dec. 31, 2024, total revenue of $12.8 billion climbed by 5.6% year over year. Perhaps the bigger story was the jump in profitability, as adjusted EPS reached $9.68, up 26% from the year prior, driven by higher pricing and Medicare reimbursement rates. Today, DaVita stands out as a compelling investment opportunity, with a combination of sustained profitable growth and an attractive valuation.</p>
<div class="lb-trans"><p>截至 2024 年 12 月 31 日的完整年度，總收入為 128 億美元，同比增長 5.6%。或許更大的故事是盈利能力的躍升，調整後的每股收益達到 9.68 美元，比去年增長 26%，這得益於更高的定價和醫療保險報銷率。如今，達維塔作為一個引人注目的投資機會脱穎而出，結合了持續的盈利增長和吸引人的估值。</p>
</div><p>Even with the stock climbing 8% over the past year, shares are trading at just 13 times its consensus 2025 EPS as a forward price-to-earnings (P/E) ratio, well below the company's 10-year average for the earnings multiple, which is closer to 17. I believe DaVita's stock is undervalued and well-positioned to generate positive returns over the next few years -- a view Buffett might agree with.</p>
<div class="lb-trans"><p>儘管過去一年股票上漲了 8%，但其股票的交易價格僅為 2025 年每股收益的 13 倍，作為前瞻性市盈率（P/E），遠低於該公司 10 年平均的收益倍數，後者接近 17。我認為達維塔的股票被低估，並且在未來幾年有良好的回報潛力——這一觀點巴菲特可能會贊同。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png" alt="" original-src="https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png"/></p>
<p>DVA PE Ratio (Forward) data by YCharts</p>
<div class="lb-trans"><p>DVA 市盈率（前瞻性）數據來源於 YCharts</p>
</div><h2>Why these stocks are winners</h2>
<div class="lb-trans"><h2>為什麼這些股票是贏家</h2>
</div><p>While the stock market may be unpredictable in the short term, Buffett's steadfast patience and commitment to a long-term strategy offer a vital lesson for every investor. In my opinion, Kroger and DaVita are great stocks for a diversified portfolio to navigate any market environment.</p>
<div class="lb-trans"><p>儘管股市在短期內可能不可預測，但巴菲特堅定的耐心和對長期戰略的承諾為每位投資者提供了重要的教訓。在我看來，克羅格和達維塔是適合多元化投資組合的優秀股票，可以應對任何市場環境。</p>
</div>

現在用 300 美元購買的最佳沃倫·巴菲特推薦股票